The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have refractory, recurrent, or advanced non-small cell lung cancer. The purpose of this study to evaluate an investigational drug, GT103 in combination with an immunotherapy drug, pembrolizumab. The safety and effects of the investigational treatment will be assessed for this study.
Participation includes a screening period, treatment cycles of 3 weeks with IV infusions of GT103 and pembrolizumab for about 2 years, and a longer term follow-up via a clinic visit or a phone call every 3 months to keep track of how you’re doing. Study specific test will be provided at no cost to you.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05617313
Compensation/Reimbursement: You may receive compensation to help with travel costs if you participate on this study.